NCT06161051

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 287 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.

Conditions

• Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation

Timeline

• Start date: 2022-10-03
• Primary completion: 2022-11-02
• Completion: 2022-12-07
• First posted: 2023-12-07
• Last updated: 2023-12-07

Locations

1 site across 1 country: United States